ZYBERNO
Stock Report
Updated Jun 11, 2026

LEXARIA BIOSCIENCE CORP. (LEXXW)

Healthcare • NASDAQ

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
32.0/100
WEAK BUSINESS
LEXARIA BIOSCIENCE CORP. (LEXXW) scores 32/100 — weak fundamentals with mixed indicators requiring careful analysis before acting.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-206.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.05x)
Operating Margin (Operational Efficiency):CRITICAL (-2,571.9%)
Return on Capital (Capital Efficiency):CRITICAL (-523.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

LEXARIA BIOSCIENCE CORP. (LEXXW) stock report — Zyberno Score 32/100 (WEAK BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, LEXXW generated -$8.71M in Owner Earnings. Capital was deployed as follows: $1.00 invested in capital expenditures. Reinvestment rate: 0.4%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$29.86K

Valuation Multiples (3)

P/B Ratio:0.00x
P/S Ratio:0.08x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$4.83M
B. Profitability Assessment

Return Metrics (5)

ROA:-162.5%
Reinvestment Rate:0.4%
Fundamental Growth Rate (g):-2.0%

Margin Analysis (3)

Operating Margin Ttm:-2,571.9%
Net Margin Ttm:-2,589.7%
Ebitda Margin:-2,557.1%

TTM Performance (3)

Gross Margin Ttm:100.0%
Operating Margin Ttm:-2,571.9%
Net Margin Ttm:-2,589.7%

Yield Metrics (2)

Earnings Yield:-$40.00K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:74.1%
Latest Earnings Filed:2026-04-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):28.3%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:26.88x
Quick Ratio:26.88x
Cash Ratio:23.76x

Leverage Analysis (3)

Debt To Equity Ttm:0.05x
Debt-to-Equity Ratio:0.05x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:5,555,611.00
Cash And Cash Equivalents:5,100,000.00
Long Term Debt:$62.33K
Net Debt:-$4.86M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $368.00K
Linear Growth: 28.3%
📊 Click to view full LEXXW Revenue analysis & methodology →
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

Gross profit TTM: $368.00K
Linear Growth: 42.1%
📊 Click to view full LEXXW Gross Profit analysis & methodology →
-$9.46M

Bottom Line Performance (3)

-$9.53M
Income Before Tax:-$11.91M
Ebitda Ttm:-9,410,052.00

Operating Expenses (5)

Operating Expenses:9,832,552.00
R And D Expense:5,746,349.00
Sga Expense:4,086,203.00
Income Tax Expense:$9.17K
Interest Expense:0.00

Expense Ratios (3)

R And D To Revenue Percentage:28,731.7%
Sga To Revenue Percentage:20,431.0%
Ebitda Margin:-2,557.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$6.49M
Current Assets:$5.77M
Ppe Net:242,931.00
Goodwill:0.00
Intangible Assets:$318.06K

Liability Structure (4)

Total Liabilities:276,997.00
Current Liabilities:214,671.00
Long Term Debt:$62.33K
Short Term Debt:$182.61K

Equity & Capital (3)

Equity:$6.21M
Retained Earnings:-$66.51M
Common Stock:220,000,000.00

Working Capital Items (3)

Accounts Receivable:42,029.00
Inventory:0.00
Accounts Payable:182,611.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:74,895.00
C. Cash Flow Analysis

Operating Activities (2)

-$8.71M-$8.71M

Investment Activities (2)

Investing Cash Flow:-$5.10K
Capital Expenditures Ttm:1.00

Financing Activities (3)

Financing Cash Flow:$3.47M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:3,474,051.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:54,500.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.40
-$0.48
Earnings Per Share Ttm:-$0.38

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$0.42

Book Value & Capital (2)

Book Value Per Share:$0.25
Cash Per Share:0.20

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.06x
Working Capital Turnover Ttm:0.07x

Receivables Management (2)

Receivables Turnover Ttm:8.76x
Days Sales Outstanding Ttm:41.69

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:24,504.78
Cash Conversion Cycle:-25,462.10
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:40.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$8.71M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.4%
Fundamental Growth Rate (g):-2.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):28.3%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):42.1%
Book Value Growth Rate (Linear):-14.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:LEXXW
Company Name:LEXARIA BIOSCIENCE CORP.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:24.89M
Shares Outstanding Basic:24.89M
Shares Outstanding Diluted:24.44M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-11 15:40:12 UTC
Data Timestamp:2026-06-11T15:40:12.522429
Scroll to Top